RDD Pharma Ltd. is a leader in the discovery, development, and commercialization of innovative therapeutics for Ano-rectal diseases. The Ano-Rectal disease market is multibillion in size and yet hardly touched by the drug industry. In the short time since its foundation in 2008, the company developed the Cappository, a proprietary drug delivery method, designed specifically to meet the challenges of administering medications to the anal region, AND completed POC trials in humans for products for the treatment of anal fissure and fecal incontinence.
RDD Pharma executes a low-risk, high reward drug development strategy by repurposing previously approved APIs for its new indications, thus benefiting from short regulatory routes, while maintaining solid IP position.
Ofakim High Tech Ventures – a technological incubator
Capital Point – publicly traded (TASE) investment company
CHF – German Private Equity Fund
OrbiMed Healthcare Fund Management
RDD Pharma is a drug-device company that developed an intra-anal drug delivery device that delivers a drug to the anal canal in a controlled manner.
The company utilizes a high-reward low-risk business model by repurposing drugs; By choosing medications that are already approved for other indications and combining them into our proprietary* drug-delivery technology, we benefit from short regulatory route while maintaining our patent protection.
20 May 2013 - RDD poster presentation at Digestive Disease Week awarded "poster of distinction" award